v3.26.3
Stock-Based Compensation Plans
9 Months Ended
Sep. 30, 2026
Share-Based Payment Arrangement, Noncash Expense [Abstract]  
Stock-Based Compensation Plans Stock-Based Compensation Plans
As of September 30, 2026, approximately 1,862,000 shares were available for future grants, assuming the maximum number of shares are issued for the performance awards outstanding, approved under the Company Stock Incentive Plans (“the Plans”). Descriptions of the Plans are included in Note (18) “Stock Compensation Plans and Other Employee Benefit Plans” of the 2025 Form 10-K.

Stock-based compensation expense recognized in the Consolidated Statements of Income was $11.9 million in the third quarter of 2026 and $10.1 million in the third quarter of 2025, and $34.9 million and $30.6 million in the nine months ended September 30, 2026 and 2025, respectively.

A summary of the Plans’ stock option activity for the nine months ended September 30, 2026 and September 30, 2025 is presented below:
Stock OptionsCommon
Shares
Weighted
Average
Strike Price
Remaining
Contractual
Term (1)
Intrinsic
Value (2)
(in thousands)
Balance at December 31, 20255,675 $44.81 
Exercised(2,325)40.97 
Outstanding at September 30, 2026
3,350 $47.47 2.3$316 
Exercisable at September 30, 2026
3,350 $47.47 2.3$316 
Stock OptionsCommon
Shares
Weighted
Average
Strike Price
Remaining
Contractual
Term (1)
Intrinsic
Value (2)
(in thousands)
Balance at December 31, 202410,825 $43.76 
Exercised(5,150)42.61 
Outstanding at September 30, 2025
5,675 $44.81 3.0$497 
Exercisable at September 30, 2025
5,675 $44.81 3.0$497 
(1)Represents the remaining weighted average contractual life in years.
(2)Aggregate intrinsic value represents the total pre-tax intrinsic value (i.e., the difference between the Company’s stock price on the last trading day of the quarter and the option exercise price, multiplied by the number of shares) that would have been received by the option holders if they had exercised their options on the last day of the quarter. Options with exercise prices above the stock price on the last trading day of the quarter are excluded from the calculation of intrinsic value. The intrinsic value will change based on the fair market value of the Company’s stock.

The aggregate intrinsic value of options exercised during the nine months ended September 30, 2026 and September 30, 2025, was approximately $250,000 and $467,000, respectively. Cash received from option exercises under the Plans for the nine months ended September 30, 2026 and September 30, 2025 was approximately $95,000 and $220,000, respectively.
A summary of the Plans’ restricted share activity for the nine months ended September 30, 2026 and September 30, 2025 is presented below:
Nine months ended September 30, 2026Nine months ended September 30, 2025
Restricted SharesCommon
Shares
Weighted
Average
Grant-Date
Fair Value
Common
Shares
Weighted
Average
Grant-Date
Fair Value
Outstanding at December 31888,398 $101.63 880,866 $90.95 
Granted267,358 153.36 256,762 133.15 
Vested and issued(289,049)93.58 (218,276)94.41 
Forfeited or canceled(30,623)126.66 (24,156)109.48 
Outstanding at September 30
836,084 $120.23 895,196 $101.71 
Vested, but deferred, at September 30
103,330 $56.63 101,820 $55.31 

A summary of the Plans’ performance-based stock award activity, based on the target level of the awards, for the nine months ended September 30, 2026 and September 30, 2025 is presented below:
Nine months ended September 30, 2026Nine months ended September 30, 2025
Performance-based Stock Common
Shares
Weighted
Average
Grant-Date
Fair Value
Common
Shares
Weighted
Average
Grant-Date
Fair Value
Outstanding at December 31377,757 $102.38 454,017 $93.57 
Granted86,224 148.35 88,257 134.58 
Added by performance factor at vesting, net9,242 — 75,461 — 
Vested and issued(196,899)90.33 (230,957)95.26 
Forfeited or canceled(2,576)121.03 (8,218)107.24 
Outstanding at September 30
273,748 $125.98 378,560 $102.35 
Vested, but deferred, at September 30
— $— 13,283 $40.87